title: Prohibition or coffee shops: regulation of amphetamine and methylphenidate for enhancement use by healthy adults.
abstract: This article analyzes appropriate public policies for enhancement use of two most important stimulant drugs: Ritalin (methylphenidate) and Adderall (mixed amphetamine salts). The author argues that appropriate regulation of cognition enhancement drugs cannot be a result of a general discussion on cognitive enhancements as such, but has to be made on a case-by-case basis. Starting from the recently proposed taxation approach to cognition enhancement drugs, the author analyzes available, moderately permissive models of regulation. After a thorough analysis of relevant characteristics of methylphenidate and amphetamine, the author concludes that a moderately liberal permissive regulation of enhancement use by healthy adults might be appropriate for extended release forms of methylphenidate. However, due to their danger profile, amphetamine and instant release forms of methylphenidate should not be made readily available to healthy adults and would need to be prohibited.
authors.affiliation: International Centre for Ethics in the Sciences and Humanities, University of Tübingen, Tübingen, Germany. veljko.dubljevic@izew.uni-tuebingen.de
authors.forename: Veljko
authors.initials: V
authors.lastname: Dubljević
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000661:Amphetamine / Q000008:administration & dosage / Q000009:adverse effects; D000662:Amphetamines / Q000008:administration & dosage / Q000009:adverse effects; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000009:adverse effects; D003071:Cognition / Q000187:drug effects; D003692:Delayed-Action Preparations; D016527:Drug Costs; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence* / Q000379:methods; D006801:Humans; D007262:Infusions, Intravenous; D001239:Inhalation; D008774:Methylphenidate / Q000008:administration & dosage / Q000009:adverse effects; D018697:Nootropic Agents / Q000008:administration & dosage / Q000009:adverse effects; D026684:Personal Autonomy; D011640:Public Policy / Q000331:legislation & jurisprudence* / Q000639:trends; D016032:Randomized Controlled Trials as Topic; D019966:Substance-Related Disorders / Q000209:etiology*; D013660:Taxes; D014481:United States
chemical_list: C090411:Adderall; D000662:Amphetamines; D000697:Central Nervous System Stimulants; D003692:Delayed-Action Preparations; D018697:Nootropic Agents; D008774:Methylphenidate; D000661:Amphetamine